Liquid biopsy for monitoring medulloblastoma

Abstract

Despite recent progress in molecular diagnostics defining four distinct medulloblastoma groups, the clinical management of these malignant childhood tumors of the cerebellum remains challenging. After surgical removal of the tumor, both cytotoxic chemotherapy and irradiation can offer additional curative benefits, but they also include a significant risk of long-term damage. Early molecular profiling aims to predict the outcome of such aggressive therapies. This prevents unnecessary damage to patients who may not need it and helps to identify those patients with remaining tumor cells who may benefit from more aggressive treatment with the intent to cure. Monitoring tumor evolution in real time allows personalized precision medicine with an immediate clinical response resulting in a better outcome. Liquid biopsy includes various methodologies already applied in numerous studies and clinical trials for common cancers including brain tumors, but information on medulloblastomas is limited. This review summarizes the recent developments of how liquid biopsy can support or even replace the standard monitoring of medulloblastomas by medical imaging or cytology and discusses what will be needed to make liquid biopsy a new gold standard in diagnosis, therapy, and follow-up of medulloblastomas for the benefit of the patients.

Keywords

Medulloblastoma / monitoring / CSF / cell-free DNA / cfDNA / circulating tumor DNA / ctDNA / biomarker / liquid biopsy / brain tumor

References

[1] Ashworth A.A case of cancer in which cells similar to those in the tumours were seen in the blood after death.Aust Med J1869;14:146

[2] Paget S.The distribution of secondary growths in cancer of the breast.The Lancet1889;133:571-3

[3] Bailey P.Medulloblastoma cerebelli: a common type of midcerebellar glioma of childhood.Arch NeurPsych1925;14:192

[4] Mandel P.Nuclear acids in human blood plasma.C R Seances Soc Biol Fil1948;142:241-3

[5] Paterson E.Cerebellar medulloblastoma: treatment by irradiation of the whole central nervous system.Acta radiol1953;39:323-36

[6] Fidler IJ.Biological behavior of malignant melanoma cells correlated to their survival in vivo.Cancer Res1975;35:218-24

[7] Leon SA,Sklaroff DM.Free DNA in the serum of cancer patients and the effect of therapy.Cancer Res1977;37:646-50

[8] Eibl RH.Induction of primitive neuroectodermal tumors following retrovirus-mediated transfer of SV40 large T antigen into neural transplants. Zülch symposium on growth control and neoplastic transformation in the brain.Clin Neuropathol1991;10:248-9

[9] Eibl RH,Jat PS.A model for primitive neuroectodermal tumors in transgenic neural transplants harboring the SV40 large T antigen.Am J Pathol1994;144:556-64 PMCID:PMC1887088

[10] Ohgaki H,Wiestler OD,Newcomb EW.p53 mutations in nonastrocytic human brain tumors.Cancer Res1991;51:6202-5

[11] Reya T,Clarke MF.Stem cells, cancer, and cancer stem cells.Nature2001;414:105-11

[12] Balaña C,Taron M.O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.Clin Cancer Res2003;9:1461-8

[13] Allard WJ,Miller MC.Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.Clin Cancer Res2004;10:6897-904

[14] Cristofanilli M,Ellis MJ.Circulating tumor cells, disease progression, and survival in metastatic breast cancer.N Engl J Med2004;351:781-91

[15] Pantel K.Circulating tumour cells in cancer patients: challenges and perspectives.Trends Mol Med2010;16:398-406

[16] Bettegowda C,Leary RJ.Detection of circulating tumor DNA in early- and late-stage human malignancies.Sci Transl Med2014;6:224ra24 PMCID:PMC4017867

[17] Sullivan JP,Madden MW.Brain tumor cells in circulation are enriched for mesenchymal gene expression.Cancer Discov2014;4:1299-309 PMCID:PMC4221467

[18] Louis DN,Reifenberger G.The 2016 world health organization classification of tumors of the central nervous system: a summary.Acta Neuropathol2016;131:803-20

[19] Donaldson J.Circulating tumor DNA: measurement and clinical utility.Annu Rev Med2018;69:223-34

[20] FDA 2018. cobas EGFR Mutation Test v2. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/cobas-egfr-mutation-test-v2 [Last accessed on 27 Sep 2022]

[21] Garzia L,Morrissy AS.A hematogenous route for medulloblastoma leptomeningeal metastases.Cell2018;172:1050-1062.e14 PMCID:PMC6346737

[22] Cohen JD,Wang Y.Detection and localization of surgically resectable cancers with a multi-analyte blood test.Science2018;359:926-30 PMCID:PMC6080308

[23] Lennon AM,Kinde I.Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.Science2020;369:eabb9601 PMCID:PMC7509949

[24] Louis DN,Wesseling P.The 2021 who classification of tumors of the central nervous system: a summary.Neuro Oncol2021;23:1231-51 PMCID:PMC8328013

[25] Packer RJ,Holmes E,Gajjar A.Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group trial A9961.Neuro Oncol2013;15:97-103 PMCID:PMC3534419

[26] Jones DT,Kool M.Dissecting the genomic complexity underlying medulloblastoma.Nature2012;488:100-5 PMCID:PMC3662966

[27] Vladoiu MC,Donovan LK.Childhood cerebellar tumours mirror conserved fetal transcriptional programs.Nature2019;572:67-73 PMCID:PMC6675628

[28] Hovestadt V,Bihannic L.Resolving medulloblastoma cellular architecture by single-cell genomics.Nature2019;572:74-9 PMCID:PMC6754173

[29] Luo W,Song W.Single-cell spatial transcriptomic analysis reveals common and divergent features of developing postnatal granule cerebellar cells and medulloblastoma.BMC Biol2021;19:135 PMCID:PMC8247169

[30] Riemondy KA,Willard N.Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma.Neuro Oncol2022;24:273-86 PMCID:PMC8804892

[31] Saylors RL,Friedman HS.Infrequent p53 gene mutations in medulloblastomas.Cancer Res1991;51:4721-3

[32] Wiestler OD,Schneemann M,von Deimling A.Oncogene complementation in fetal brain transplants.Cancer Res1992;52:3760-7.

[33] Radner H,Eibl RH.Tumor induction by ras and myc oncogenes in fetal and neonatal brain: modulating effects of developmental stage and retroviral dose.Acta Neuropathol1993;86:456-65

[34] Kleihues P,Eibl RH.Type and frequency of p53 mutations in tumors of the nervous system and its coverings. In: Wiestler OD, Schlegel U, Schramm J, editors. Molecular neuro-oncology and its impact on the clinical management of brain tumors. Berlin: Springer Berlin Heidelberg; 1994. p. 25-31.

[35] Louis DN,Chung RY.Comparative study of p53 gene and protein alterations in human astrocytic tumors.J Neuropathol Exp Neurol1993;52:31-8

[36] Ohgaki H,Schwab M.Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system.Mol Carcinog1993;8:74-80

[37] von Deimling A,Ohgaki H.p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma.Cancer Res1992;52:2987-90

[38] Preuss I,Eichhorn U.Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue.Cancer Detect Prev1996;20:130-6

[39] Preuss I,Haas S.O6-methylguanine-DNA methyltransferase activity in breast and brain tumors.Int J Cancer1995;61:321-6

[40] Wiestler OD,Eibl RH,Aguzzi A.Retrovirus-mediated oncogene transfer into neural transplants.Brain Pathol1992;2:47-59

[41] Wiestler OD,Eibl RH.A new approach to the molecular basis of neoplastic transformation in the brain.Neuropathol Appl Neurobiol1992;18:443-53

[42] Martínez-Ricarte F,Martínez-Sáez E.Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid.Clin Cancer Res2018;24:2812-9

[43] Miller AM,Pentsova EI.Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.Nature2019;565:654-8 PMCID:PMC6457907

[44] Mouliere F,Chandrananda D.Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients.EMBO Mol Med2018;10:e9323 PMCID:PMC6284385

[45] Pan Y,Liu Q.Current advances and future perspectives of cerebrospinal fluid biopsy in midline brain malignancies.Curr Treat Options Oncol2019;20:88

[46] Wang Y,Zhang M.Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord.Proc Natl Acad Sci U S A2015;112:9704-9 PMCID:PMC4534284

[47] De Mattos-Arruda L,Ng CKY.Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.Nat Commun2015;6:8839 PMCID:PMC5426516

[48] SMART. Servier Med Art. Available from: https://smart.servier.com/ [Last accessed on Sep 27 2022]

[49] Creative Commons - Attribution 3.0 Unported - CC BY 3.0. Available from: https://creativecommons.org/licenses/by/3.0/ [Last accessed on Sep 27 2022]

[50] Eibl RH.Liquid biopsy and primary brain tumors.Cancers (Basel)2021;13:5429 PMCID:PMC8582521

[51] Eibl RH.Cell-free DNA as a biomarker in cancer.Extracell Vesicles Circ Nucleic Acids2022;3:178-98

[52] Müller C,Auer M.Hematogenous dissemination of glioblastoma multiforme.Sci Transl Med2014;6:247ra101

[53] Perryman L.Brain cancer spreads.Sci Transl Med2014;6:247fs28

[54] Macarthur KM,Chandrasekaran S.Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay.Cancer Res2014;74:2152-9 PMCID:PMC4144786

[55] Krol I,Maurer M.Detection of circulating tumour cell clusters in human glioblastoma.Br J Cancer2018;119:487-91 PMCID:PMC6134152

[56] Gao F,Jiang H.Circulating tumor cell is a common property of brain glioma and promotes the monitoring system.Oncotarget2016;7:71330-40 PMCID:PMC5342081

[57] Eibl RH,Moll J.Expression of variant CD44 epitopes in human astrocytic brain tumors.J Neurooncol1995;26:165-70

[58] Eibl RH.Single-molecule studies of integrins by AFM-based force spectroscopy on living cells. In: Bhushan B, editor. Scanning probe microscopy in nanoscience and nanotechnology 3. Berlin, Heidelberg: Springer; 2013. p. 137-69.

[59] Eibl RH.Molecular resolution of cell adhesion forces.IEE Proc Nanobiotechnol2004;151:128

[60] Eibl RH.Atomic force microscopy measurements of protein-ligand interactions on living cells. protein-ligand interactions. New Jersey: Humana Press; 2005. p. 439-50.

[61] Eibl RH.Comment on “A method to measure cellular adhesion utilizing a polymer micro-cantilever” [Appl Phys Lett 2013;103:123702].Appl Phys Lett2014;104:236103 PMCID:PMC8587856

[62] Eibl RH.Cell adhesion receptors studied by AFM-based single-molecule force spectroscopy. In: Bhushan B, editor. Scanning probe microscopy in nanoscience and nanotechnology 2. Berlin, Heidelberg: Springer; 2011. p. 197-215.

[63] Eibl RH.Direct force measurements of receptor-ligand interactions on living cells. In: Bhushan B, Fuchs H, editors. Applied scanning probe methods XII: characterization. Berlin, Heidelberg: Springer; 2009. p. 1-31.

[64] Eibl RH. First measurement of physiologic VLA-4 activation by SDF-1 at the single-molecule level on a living cell. In: Hinterdorfer P, Schütz G, Pohl P, editors. Proceedings of the VIII. Linz Winter Workshop 2006: Advances in Single Molecule Research for Biology and Nanoscience. Linz: Trauner; 2006. p. 40-3.

[65] Eibl RH. AFM-based adhesion measurements of single receptor-ligand bonds on living cells. In: Pandalai SG, editor. Recent research developments in biophysics. Trivandrum: Transworld Research Network; 2004. p. 235-46. Available from: https://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17751719 [Last accessed on Sep 27 2022]

[66] Chen WW,Liau LM.BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles.Mol Ther Nucleic Acids2013;2:e109 PMCID:PMC3732870

[67] Yasui T,Ito S.Unveiling massive numbers of cancer-related urinary-microRNA candidates via nanowires.Sci Adv2017;3:e1701133 PMCID:PMC5744465

[68] Floyd D.Micro-masters of glioblastoma biology and therapy: increasingly recognized roles for microRNAs.Neuro Oncol2014;16:622-7 PMCID:PMC3984565

[69] Kitano Y,Ohka F.Urinary microRNA-based diagnostic model for central nervous system tumors using nanowire scaffolds.ACS Appl Mater Interfaces2021;13:17316-29

[70] Lee B,Pokhrel R.Medulloblastoma cerebrospinal fluid reveals metabolites and lipids indicative of hypoxia and cancer-specific RNAs.Acta Neuropathol Commun2022;10:25 PMCID:PMC8867780

[71] Hao X,Sun H.Urinary protein biomarkers for pediatric medulloblastoma.J Proteomics2020;225:103832

[72] Gonzalez-Beltran AN,Ampe C.Community standards for open cell migration data.Gigascience2020;9:giaa041 PMCID:PMC7317087

[73] Escudero L,Arias A.Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma.Nat Commun2020;11:5376 PMCID:PMC7591522

[74] Li J,Lee M.Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma.Sci Adv2020;6:eabb5427 PMCID:PMC7567591

[75] Liu APY,Kumar R.Serial assessment of measurable residual disease in medulloblastoma liquid biopsies.Cancer Cell2021;39:1519-1530.e4

[76] Sun Y,Ren S.Exploring genetic alterations in circulating tumor DNA from cerebrospinal fluid of pediatric medulloblastoma.Sci Rep2021;11:5638 PMCID:PMC7952732

[77] Pagès M,Gydush G.Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.Neuro Oncol2022;24:1352-63 PMCID:PMC9340641

[78] Home - ClinicalTrials. gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03936465?term=NCT03936465&draw=2&rank=1 [Last accessed on Sep 27 2022]